Thematic review series: Fat-soluble vitamins: Vitamin K: Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis

Journal of Lipid Research

Volumn 55, Issue 3, 2014, Pages 345-362

  Shearer, Martin J ^a   Newman, Paul ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Anticoagulants; Menaquinones; Phylloquinone; UbiA prenyltransferase containing domain 1; Vitamin K antagonists; Vitamin K dehydrogenase; Vitamin K epoxide; Vitamin K epoxide reductase; Warfarin; Warfarin resistance; carboxyglutamate proteins

Indexed keywords

1,3 INDANDIONE DERIVATIVE; 4 HYDROXYCOUMARIN DERIVATIVE; ACENOCOUMAROL; CEFAMANDOLE; COUMARIN; DICOUMAROL; DIMETHYLALLYLTRANSFERASE; LATAMOXEF; MENADIONE; MENADIONE EPOXIDE; MENATETRENONE; PHENINDIONE; PHENPROCOUMON; PHYTOMENADIONE; PROTEIN NQO1; PROTEIN VKORL1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UBIA PRENYLTRANSFERASE CONTAINING DOMAIN 1; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; DRUG DERIVATIVE; FARNOQUINONE; PHYTOMENADIONE OXIDE; TERE1 PROTEIN, HUMAN;

BIOSYNTHESIS; BONE METABOLISM; CATABOLISM; CHEMICAL STRUCTURE; CYTOLOGY; DETOXIFICATION; DIET; DRUG MECHANISM; DRUG RESISTANCE; GENE IDENTIFICATION; HUMAN; IN VIVO STUDY; INTESTINE ABSORPTION; KNOCKOUT MOUSE; MALIGNANT NEOPLASTIC DISEASE; NEONATAL HEMORRHAGE; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STORAGE; VITAMIN K METABOLISM; ANIMAL; CHEMISTRY; INTESTINE; MENAQUINONES; METABOLISM; UBIA PRENYLTRANSFERASE-CONTAINING DOMAIN 1; VITAMIN K ANTAGONISTS; VITAMIN K DEHYDROGENASE; WARFARIN RESISTANCE; Γ-CARBOXYGLUTAMATE PROTEINS;

ANTICOAGULANTS; MENAQUINONES; PHYLLOQUINONE; UBIA PRENYLTRANSFERASE-CONTAINING DOMAIN 1; VITAMIN K ANTAGONISTS; VITAMIN K DEHYDROGENASE; VITAMIN K EPOXIDE; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; WARFARIN RESISTANCE; Γ-CARBOXYGLUTAMATE PROTEINS;

ANIMALS; BIOSYNTHETIC PATHWAYS; DIET; DIMETHYLALLYLTRANSTRANSFERASE; HUMANS; INTESTINES; MOLECULAR STRUCTURE; VITAMIN K 1; VITAMIN K 2; VITAMIN K EPOXIDE REDUCTASES;

EID: 84894789825     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R045559     Document Type: Review

References (143)

1. Stenflo, J., P. Fernlund, W. Egan, and P. Roepstorff. 1974. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc. Natl. Acad. Sci. USA. 71: 2730-2733.
2. Nelsestuen, G. L., T. H. Zytkovicz, and J. B. Howard. 1974. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J. Biol. Chem. 249: 6347-6350.
3. Booth, S. L. 2009. Roles for vitamin K beyond coagulation. Annu. Rev. Nutr. 29: 89-110.
4. Gundberg, C. M., J. B. Lian, and S. L. Booth. 2012. Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv. Nutr. 3: 149-157.
5. Cancela, M. L., N. Conceição, and V. Laizé. 2012. Gla-rich protein, a new player in tissue calcification. Adv. Nutr. 3: 174-181.
6. Schurgers, L. J., J. Uitto, and C. P. Reutelingsperger. 2013. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol. Med. 19: 217-226.
7. Booth, S. L., A. Centi, S. R. Smith, and C. Gundberg. 2013. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat. Rev. Endocrinol. 9: 43-55.
8. Ferland, G. 2012. Vitamin K and the nervous system: an overview of its actions. Adv. Nutr. 3: 204-212.
9. Bellido-Martín, L., and P. G. de Frutos. 2008. Vitamin K-dependent actions of gas-6. Vitam. Horm. 78: 185-209.
10. Laurance, S., C. A. Lemarié, and M. D. Blostein. 2012. Growth arrest-specific gene 6 (gas 6) and vascular hemostasis. Adv. Nutr. 3: 196-203.
11. Shearer, M. J., and P. Newman. 2008. Metabolism and cell biology of vitamin K. Thromb. Haemost. 100: 530-547.
12. Shearer, M. J., X. Fu, and S. L. Booth. 2012. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv. Nutr. 3: 182-195.
13. Rost, S., A. Fregin, V. Ivaskevicius, E. Conzelmann, K. Hörtnagel, H. J. Pelz, K. Lappegard, E. Seifried, I. Scharrer, E. G. Tuddenham, et al. 2004. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 427: 537-541. (Pubitemid 38209110)
14. Li, T., C. Y. Chang, D. Y. Jin, P. J. Lin, A. Khvorova, and D. W. Stafford. 2004. Identification of the gene for vitamin K epoxide reductase. Nature. 427: 541-544. (Pubitemid 38209111)
15. Nakagawa, K., Y. Hirota, N. Sawada, N. Yuge, M. Watanabe, Y. Uchino, N. Okuda, Y. Shimomura, Y. Suhara, and T. Okano. 2010. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature. 468: 117-121.
16. Langemann, A., and O. Isler. 1965. Chemistry of isoprenoid quinones. In Biochemistry of Quinones. R. A. Morton, editor. Academic Press, London. 89-147.
17. Bolton-Smith, C., R. J. G. Price, S. T. Fenton, D. J. Harrington, and M. J. Shearer. 2000. Compilation of a provisional UK database for the phylloquinone (vitamin K1) content of foods. Br. J. Nutr. 83: 389-399. (Pubitemid 30189284)
18. 1): variation with socio-demographic and lifestyle factors in a national sample of British elderly people. Br. J. Nutr. 87: 605-613.
19. Holmes, M. V., B. J. Hunt, and M. J. Shearer. 2012. The role of dietary vitamin K in the management of oral vitamin K antagonists. Blood Rev. 26: 1-14.
20. Nowicka, B., and J. Kruk. 2010. Occurrence, biosynthesis and function of isoprenoid quinones. Biochim. Biophys. Acta. 1797: 1587-1605.
21. Collins, M. D., and D. Jones. 1981. Distribution of isoprenoid quinone structural types in bacteria and their taxonomic implications. Microbiol. Rev. 45: 316-354. (Pubitemid 11032202)
22. Fernandez, F., and M. D. Collins. 1987. Vitamin K composition of anaerobic gut bacteria. FEMS Microbiol. Lett. 41: 175-180. (Pubitemid 17048579)
23. Conly, J. M., and K. Stein. 1992. Quantitative and qualitative measurements of K vitamins in human intestinal contents. Am. J. Gastroenterol. 87: 311-316.
24. Schurgers, L. J., J. M. Geleijnse, D. E. Grobbee, H. A. P. Pols, A. Hofman, J. C. M. Witteman, and C. Vermeer. 1999. Nutritional intake of vitamins K1 (phylloquinone) and K2 (menaquinone) in the Netherlands. J. Nutr. Environ. Med. 9: 115-122. (Pubitemid 29290436)
25. Nimptsch, K., S. Rohrmann, and J. Linseisen. 2008. Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). Am. J. Clin. Nutr. 87: 985-992. (Pubitemid 351549245)
26. Schurgers, L. J., and C. Vermeer. 2000. Determination of phylloquinone in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 30: 298-307. (Pubitemid 32453662)
27. Hojo, K., R. Watanabe, T. Mori, and N. Taketomo. 2007. Quantitative measurement of tetrahydromenaquinone-9 in cheese fermented by propionibacteria. J. Dairy Sci. 90: 4078-4083. (Pubitemid 350045182)
28. Burt, V. T., E. Bee, and J. F. Pennock. 1977. The formation of menaquinone-4 (vitamin K) and its oxide in some marine invertebrates. Biochem. J. 162: 297-302. (Pubitemid 8024014)
29. Walther, B., J. P. Karl, S. L. Booth, and P. Boyaval. 2013. Menaquinones, bacteria, and the food supply: the relevance of dairy and fermented food products to vitamin K requirements. Adv. Nutr. 4: 463-473.
30. Jones, K. S., L. J. Bluck, L. Y. Wang, A. M. Stephen, C. J. Prynne, and W. A. Coward. 2009. The effect of different meals on the absorption of different meals on the absorption of stable isotopela-belled phylloquinone. Br. J. Nutr. 102: 1195-1202.
31. Suttie, J. W. 2009. Vitamin K in Health and Disease. CRC Press, Boca Raton, FL.
32. Schurgers, L. J., M. J. Shearer, K. Hamulyák, E. Stöcklin, and C. Vermeer. 2004. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood. 104: 2682-2689. (Pubitemid 39434948)
33. Schurgers, L. J., K. J. Teunissen, K. Hamulyák, M. H. Knapen, H. Vik, and C. Vermeer. 2007. Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 109: 3279-3283. (Pubitemid 46572513)
34. 2) on the stability of oral anticoagulant treatment: dose response relationship in healthy volunteers. J. Thromb. Haemost. 11: 1085-1092.
35. O'Byrne, S. M., and W. S. Blaner. 2013. Retinol and retinyl esters: biochemistry and physiology. J. Lipid Res. 54: 1731-1743.
36. Traber, M. G. 2013. Mechanisms for the prevention of vitamin E excess. J. Lipid Res. 54: 2295-2306.
37. 1) analysis in human serum. Biomed. Chromatogr. 23: 1276-1282.
38. Tsugawa, N., M. Shiraki, Y. Suhara, M. Kamao, K. Tanaka, and T. Okano. 2006. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for gamma-carboxylation of osteocalcin. Am. J. Clin. Nutr. 83: 380-386. (Pubitemid 44713201)
39. Kohlmeier, M., A. Salomon, J. Saupe, and M. J. Shearer. 1996. Transport of vitamin K to bone in humans. J. Nutr. 126: 1192S-1196S. (Pubitemid 26105657)
40. Lamon-Fava, S., J. A. Sadowski, K. W. Davidson, M. E. O'Brien, J. R. McNamara, and E. J. Schaefer. 1998. Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am. J. Clin. Nutr. 67: 1226-1231. (Pubitemid 28259511)
41. Schurgers, L. J., and C. Vermeer. 2002. Differential lipoprotein transport pathways of K-vitamins in healthy adults. Biochim. Biophys. Acta. 1570: 27-32. (Pubitemid 34311890)
42. Erkkilä, A. T., A. H. Lichtenstein, G. G. Dolnikowski, M. A. Grusak, S. M. Jalbert, K. A. Aquino, J. W. Peterson, and S. L. Booth. 2004. Plasma transport of vitamin K in men using deuterium-labeled collard greens. Metabolism. 53: 215-221. (Pubitemid 38168894)
43. Shearer, M. J., A. McBurney, and P. Barkhan. 1974. Studies on the absorption and metabolism of phylloquinone (vitamin K1) in man. Vitam. Horm. 32: 513-542.
44. Jones, K. S., L. J. Bluck, L. Y. Wang, and W. A. Coward. 2008. A stable isotope method for the simultaneous measurement of vitamin K1 (phylloquinone) kinetics and absorption. Eur. J. Clin. Nutr. 62: 1273-1281.
45. Newman, P., F. Bonello, A. S. Wierzbicki, P. Lumb, G. F. Savidge, and M. J. Shearer. 2002. The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E. J. Bone Miner. Res. 17: 426-433. (Pubitemid 34171757)
46. Niemeier, A., M. Kassem, K. Toedter, D. Wendt, W. Ruether, U. Beisiegel, and J. Heeren. 2005. Expression of LRP1 by human osteoblasts: a mechanism for the delivery of lipoproteins and vitamin K1 to bone. J. Bone Miner. Res. 20: 283-293.
47. Niemeier, A., D. Niedzielska, R. Secer, A. Schilling, M. Merkel, C. Enrich, P. C. Rensen, and J. Heeren. 2008. Uptake of postprandial lipoproteins into bone in vivo: impact on osteoblast function. Bone. 43: 230-237.
48. Cooper, A. D. 1997. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38: 2173-2192. (Pubitemid 27495377)
49. Shearer, M. J., P. T. McCarthy, O. E. Crampton, and M. B. Mattock. 1988. The assessment of human vitamin K status from tissue measurements. In Current Advances in Vitamin K Research. J. W. Suttie, editor. Elsevier, New York. 437-452.
50. Thijssen, H. H., and M. J. Drittij-Reijnders. 1996. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Br. J. Nutr. 75: 121-127. (Pubitemid 26059371)
51. Thijssen, H. H., and M. J. Drittij-Reijnders. 1994. Vitamin K distribution in rat tissues: dietary phylloquinone is a source of tissue menaquinone-4. Br. J. Nutr. 72: 415-425. (Pubitemid 24293471)
52. Thijssen, H. H., M. J. Drittij-Reijnders, and M. A. Fisher. 1996. Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations. J. Nutr. 126: 537-543. (Pubitemid 26055786)
53. Usui, Y., H. Tanimura, N. Nishimura, N. Kobayashi, T. Okanoue, and K. Ozawa. 1990. Vitamin K concentrations in the plasma and liver of surgical patients. Am. J. Clin. Nutr. 51: 846-852.
54. Shearer, M. J., A. Bach, and M. Kohlmeier. 1996. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J. Nutr. 126: 1181S-1186S. (Pubitemid 26105655)
55. McBurney, A., M. J. Shearer, and P. Barkhan. 1980. Preparative isolation and characterization of the urinary aglycones of vitamin K (phylloquinone) in man. Biochem. Med. 24: 250-267. (Pubitemid 11142177)
56. Harrington, D. J., R. Soper, C. Edwards, G. F. Savidge, S. J. Hodges, and M. J. Shearer. 2005. Determination of the urinary aglycone metabolites of vitamin K by HPLC with redox-mode electrochemical detection. J. Lipid Res. 46: 1053-1060.
57. 1 on phylloquinone metabolism. Arch. Biochem. Biophys. 147: 430-435.
58. McDonald, M. G., M. J. Rieder, M. Nakano, C. K. Hsia, and A. E. Rettie. 2009. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75: 1337-1346.
59. Caldwell, M. D., T. Awad, J. A. Johnson, B. F. Gage, M. Falkowski, P. Gardina, J. Hubbard, Y. Turpaz, T. Y. Langaee, C. Eby, et al. 2008. CYP4F2 genetic variant alters required warfarin dose. Blood. 111: 4106-4112.
60. Spohn, G., A. Kleinridders, F. T. Wunderlich, M. Watzka, F. Zaucke, K. Blumbach, C. Geisen, E. Seifried, C. Müller, M. Paulsson, et al. 2009. VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding. Thromb. Haemost. 101: 1044-1050.
61. Matschiner, J. T., R. G. Bell, J. M. Amelotti, and T. E. Knauer. 1970. Isolation and characterization of a new metabolite of phylloquinone in the rat. Biochim. Biophys. Acta. 201: 309-315.
62. Bell, R. G., and J. T. Matschiner. 1972. Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature. 237: 32-33.
63. Fregin, A., S. Rost, W. Wolz, A. Krebsova, C. R. Muller, and J. Oldenburg. 2002. Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16. Blood. 100: 3229-3232. (Pubitemid 35217071)
64. Kohn, M. H., and H. J. Pelz. 2000. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood. 96: 1996-1998. (Pubitemid 30661089)
65. Chu, P. H., T. Y. Huang, J. Williams, and D. W. Stafford. 2006. Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2. Proc. Natl. Acad. Sci. USA. 103: 19308-19313. (Pubitemid 46026028)
66. Oldenburg, J., M. Marinova, C. Müller-Reible, and M. Watzka. 2008. The vitamin K cycle. Vitam. Horm. 78: 35-62.
67. Tie, J-K., and D. W. Stafford. 2008. Structure and function of vitamin K epoxide reductase. Vitam. Horm. 78: 103-130.
68. Van Horn, W. D. 2013. Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reducatase-like1. Crit. Rev. Biochem. Mol. Biol. 48: 357-372.
69. Link, K. P. 1959. The discovery of dicumarol and its sequels. Circulation. 19: 97-107.
70. Shearer, M. J., H. Bechtold, K. Andrassy, J. Koderisch, P. T. McCarthy, D. Trenk, E. Jähnchen, and E. Ritz. 1988. Mechanism of cephalosporin- induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J. Clin. Pharmacol. 28: 88-95.
71. Gebauer, M. 2007. Synthesis and structure activity-relationships of novel warfarin derivatives. Bioorg. Med. Chem. 15: 2414-2420. (Pubitemid 46240909)
72. Price, P. A., and Y. Kaneda. 1987. Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb. Res. 46: 121-131. (Pubitemid 17068374)
73. Wallin, R., and L. F. Martin. 1987. Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem. J. 241: 389-396. (Pubitemid 17234174)
74. Wallin, R., S. D. Patrick, and L. F. Martin. 1989. Vitamin K1 reduction in human liver. Location of the coumarin-drug-insensitive enzyme. Biochem. J. 260: 879-884. (Pubitemid 19155683)
75. Wallin, R., O. Gebhardt, and H. Prydz. 1978. NAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reaction. Biochem. J. 169: 95-101. (Pubitemid 8270566)
76. Wallin, R., and S. Hutson. 1982. Vitamin K-dependent carboxylation. Evidence that at least two microsomal dehydrogenases reduce vitamin K1 to support carboxylation. J. Biol. Chem. 257: 1583-1586. (Pubitemid 12157106)
77. Wallin, R., and L. F. Martin. 1985. Vitamin K-dependent carboxylation and vitamin K metabolism in the liver. Effects of warfarin. J. Clin. Invest. 76: 1879-1884. (Pubitemid 16196058)
78. Wallin, R. 1986. Vitamin K antagonism of coumarin anticoagulation. A dehydrogenase pathway in rat liver is responsible for the antagonistic effect. Biochem. J. 236: 685-693. (Pubitemid 16067112)
79. Finkelstein, Y., D. Chitayat, T. Schechter, S. Keating, A. Toi, and G. Koren. 2005. Motherrisk rounds. Warfarin embryopathy following low-dose maternal exposure. J. Obstet. Gynaecol. Can. 27: 702-706.
80. Pauli, R. M., J. B. Lian, D. F. Mosher, and J. W. Suttie. 1987. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives. Am. J. Hum. Genet. 41: 566-583. (Pubitemid 18031530)
81. Menger, H., A. E. Lin, H. V. Toriello, G. Bernert, and J. W. Spranger. 1997. Vitamin K deficiency embryopathy: a phenocopy of the warfarin embryopathy due to a disorder of embryonic vitamin K metabolism. Am. J. Med. Genet. 72: 129-134. (Pubitemid 27426076)
82. Munroe, P. B., R. O. Olgunturk, J. P. Fryns, L. van Maldergem, F. Ziereisen, B. Yuksel, R. M. Gardiner, and E. Chung. 1999. Mutations in the gene encoding the human matrix Gla protein cause Keutal syndrome. Nat. Genet. 21: 142-144. (Pubitemid 29036302)
83. Tie, J. K., C. Nicchitta, G. von Heijne, and D. W. Stafford. 2005. Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J. Biol. Chem. 280: 16410-16416. (Pubitemid 40616771)
84. Jin, D. Y., J. K. Tie, and D. W. Stafford. 2007. The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry. 46: 7279-7283.
85. Tie, J. K., D. Y. Jin, D. L. Straight, and D. W. Stafford. 2011. Functional study of the vitamin K cycle in mammalian cells. Blood. 117: 2967-2974.
86. Tie, J. K., D. Y. Jin, K. Tie, and D. W. Stafford. 2013. Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells. J. Thromb. Haemost. 11: 1556-1564.
87. O'Reilly, R. A., P. M. Aggeler, M. S. Hoag, L. S. Leong, and M. L. Kropatkin. 1964. Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs. The first reported kindred. N. Engl. J. Med. 271: 809-815.
88. Boyle, C. M. 1960. Case of apparent resistance of Rattus norvegicus Berkenhout to anticoagulant poisons. Nature. 188: 517.
89. Lund, M. 1964. Resistance to warfarin in the common rat. Nature. 203: 778.
90. Rowe, F. P., C. J. Plant, and A. Bradfield. 1981. Trials of the anticoagulant rodenticides bromadiolone and difenacoum against the house mouse (Mus musculus L.). J. Hyg. (Lond.). 87: 171-177. (Pubitemid 11014735)
91. Greaves, J. H., D. S. Shepherd, and R. Quy. 1982. Field trials of second-generation anticoagulants against difenacoum-resistant Norway rat populations. J. Hyg. (Lond.). 89: 295-301. (Pubitemid 13250593)
92. Hodroge, A., B. Matagrin, C. Moreau, I. Foure, A. Hammed, E. Benoit, and V. Lattard. 2012. VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity. J. Thromb. Haemost. 10: 2535-2543.
93. Pelz, H. J., S. Rost, M. Hünerberg, A. Fregin, A. C. Heiberg, K. Baert, A. D. MacNicoll, C. V. Prescott, A. S. Walker, J. Oldenburg, et al. 2005. The genetic basis of resistance to anticoagulants in rodents. Genetics. 170: 1839-1847. (Pubitemid 41362835)
94. Rost, S., H. J. Pelz, S. Menzel, A. D. MacNicoll, V. Leon, K. J. Song, T. Jakel, J. Oldenburg, and C. R. Muller. 2009. Novel mutations in the VKORC1 gene of wild rats and mice-a response to 50 years of selection pressure by warfarin? BMC Genet. 10: 4.
95. Hodroge, A., C. Longin-Sauvageon, I. Fourel, E. Benoit, and V. Lattard. 2011. Biochemical characterization of spontaneous mutants of rat VKORC1 involved in the resistance to antivitamin K anticoagulants. Arch. Biochem. Biophys. 515: 14-20.
96. Ma, Q., K. Cui, F. Xiao, A. Y. Lu, and C. S. Yang. 1992. Identification of a glycine-rich sequence as an NAD(P)H-binding site and tyrosine 128 as a dicumarol-binding site in rat liver NAD(P)H:quinone oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 267: 22298-22304.
97. Oldenburg, J., C. G. Bevans, C. R. Muller, and M. Watzka. 2006. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid. Redox Signal. 8: 347-353. (Pubitemid 43741305)
98. Fregin, A., K. J. Czogalla, J. Gansler, S. Rost, M. Taverna, M. Watzka, C. G. Bevans, C. R. Muller, and J. Oldenburg. 2013. A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay. J. Thromb. Haemost. 11: 872-880.
99. Harrington, D. J., S. Siddiq, S. L. Allford, M. J. Shearer, and A. D. Mumford. 2011. More on: endoplasmic reticulum loop VKORC1 substitutions cause warfarin resistance but do not diminish gamma-carboxylation of the vitamin K-dependent coagulation factors. J. Thromb. Haemost. 9: 1093-1095.
100. Ernster, L. 1967. DT-diaphorase. Methods Enzymol. 10: 309-317.
101. Lind, C., E. Cadenas, P. Hochstein, and L. Ernster. 1990. DT-diaphorase: purification, properties, and function. Methods Enzymol. 186: 287-301. (Pubitemid 20279970)
102. Fasco, M. J., and L. M. Principe. 1982. Vitamin K1 hydroquinone formation catalyzed by DT-diaphorase. Biochem. Biophys. Res. Commun. 104: 187-192. (Pubitemid 12146297)
103. Gong, X., R. Gutala, and A. K. Jaiswal. 2008. Quinone oxidoreductases and vitamin K metabolism. Vitam. Horm. 78: 85-101.
104. Hollander, P. M., and L. Ernster. 1975. Studies on the reaction mechanism of DT Diaphorase. Action of dead-end inhibitors and effects of phospholipids. Arch. Biochem. Biophys. 169: 560-567.
105. Preusch, P. C., and D. M. Smalley. 1990. Vitamin K1 2,3-epoxide and quinone reduction: mechanism and inhibition. Free Radic. Res. Commun. 8: 401-415. (Pubitemid 20262583)
106. Park, B. K., and J. B. Leck. 1982. A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem. Pharmacol. 31: 3635-3639. (Pubitemid 13244130)
107. Martius, C., R. Ganser, and A. Viviani. 1975. The enzymatic reduction of K-vitamins incorporated in the membrane of liposomes. FEBS Lett. 59: 13-14.
108. Ingram, B. O., J. L. Turbyfill, P. J. Bledsoe, A. K. Jaiswal, and D. W. Stafford. 2013. Assessment of the contribution of NAD(P) H-dependent quinone oxidoreductase 1 (NQO1) to the reduction of vitamin K in wild-type and NQO1-deficient mice. Biochem. J. 456: 47-54.
109. Robertson, H. M. 2004. Genes encoding vitamin-K epoxide reductase are present in Drosophila and trypanosomatid protists. Genetics. 168: 1077-1080. (Pubitemid 39491481)
110. Westhofen, P., M. Watzka, M. Marinova, M. Hass, G. Kirfel, J. Muller, C. G. Bevans, C. R. Muller, and J. Oldenburg. 2011. Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant function. J. Biol. Chem. 286: 15085-15094.
111. Hammed, A., B. Matagrin, G. Spohn, C. Prouillac, E. Benoit, and V. Lattard. 2013. VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy. J. Biol. Chem. 288: 28733-28742.
112. WHO IARC-Monographs on the evaluation of carcinogenic risks to humans. Vol. 76: Some antiviral and antineoplastic drugs, and other pharmaceutical agents. Lyon, France: IARC Press. 2000. 417-486.
113. Vest, M. 1966. Vitamin K in medical practice: pediatrics. Vitam. Horm. 24: 649-663.
114. Thor, H., M. T. Smith, P. Hartzell, G. Bellomo, S. A. Jewell, and S. Orrenius. 1982. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. J. Biol. Chem. 257: 12419-12425. (Pubitemid 13180138)
115. Brown, P. C., D. M. Dulik, and T. W. Jones. 1991. The toxicity of menadione (2-methyl-1,4-naphthoquinone) and two thioether conjugates studied with isolated renal epithelial cells. Arch. Biochem. Biophys. 285: 187-196.
116. Di Monte, D., D. Ross, G. Bellomo, L. Eklöw, and S. Orrenius. 1984. Alterations in intracellular thiol homeostasis during the metabolism of menadione by isolated rat hepatocytes. Arch. Biochem. Biophys. 235: 334-342. (Pubitemid 15158792)
117. Canady, W. J., and J. H. Roe. 1956. Studies on the reaction of menadione with blood and denatured proteins. J. Biol. Chem. 220: 571-582.
118. Lee, J. Y., O. N. Bae, S. M. Chung, M. Y. Lee, and J. H. Chung. 2001. Menadione induces endothelial dysfunction mediated by oxidative stress and arylation. Chem. Biol. Interact. 137: 169-183.
119. Radjendirane, V., P. Joseph, Y. H. Lee, S. Kimura, A. J. Klein-Szanto, F. J. Gonzalez, and A. K. Jaiswal. 1998. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J. Biol. Chem. 273: 7382-7389. (Pubitemid 28152759)
120. Thijssen, H. H., L. M. Vervoort, L. J. Schurgers, and M. J. Shearer. 2006. Menadione is a metabolite of oral vitamin K. Br. J. Nutr. 95: 260-266.
121. Al Rajabi, A., S. L. Booth, J. W. Peterson, S. W. Choi, J. W. Suttie, M. K. Shea, B. Miao, M. A. Grusak, and X. Fu. 2012. Deuterium-labeled phylloquinone has tissue-specific conversion to menaqunone-4 among Fischer 344 male rats. J. Nutr. 142: 841-845.
122. 2) in rats. J. Biol. Chem. 288: 33071-33080.
123. Mukai, K., H. Morimoto, S. Kikuchi, and S. Nagaoka. 1993. Kinetic study of free-radical-scavenging action of biological hydroquinones (reduced forms of ubiquinone, vitamin K and tocopherol quinone) in solution. Biochim. Biophys. Acta. 1157: 313-317. (Pubitemid 23207814)
124. Vervoort, L. M. T., J. E. Ronden, and H. H. W. Thijssen. 1997. The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation. Biochem. Pharmacol. 54: 871-876. (Pubitemid 27404594)
125. Li, J., J. C. Lin, H. Wang, J. W. Peterson, B. C. Furie, B. Furie, S. L. Booth, J. J. Volpe, and P. A. Rosenberg. 2003. Novel role of vitamin K in preventing oxidative injury to developing oligodendrocytes and neurons. J. Neurosci. 23: 5816-5826. (Pubitemid 36807861)
126. Li, J., H. Wang, and P. A. Rosenberg. 2009. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. J. Neurosci. Res. 87: 1997-2005.
127. 2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. J. Biol. Chem. 283: 11270-11279.
128. Davidson, R. T., A. L. Foley, J. A. Engelke, and J. W. Suttie. 1998. Conversion of dietary phylloquinone to tissue menaquinone-4 in rats is not dependent on gut bacteria. J. Nutr. 128: 220-223. (Pubitemid 28124990)
129. Ronden, J. E., M. J. Drittij-Reijnders, C. Vermeer, and H. H. Thijssen. 1998. Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat. Biochim. Biophys. Acta. 1379: 69-75. (Pubitemid 28045556)
130. 2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science. 336: 1306-1310.
131. Hegarty, J. M., H. Yang, and N. C. Chi. 2013. UBIAD1-mediated vitamin K2 synthesis is required for vascular endothelial cell survival and development. Development. 140: 1713-1719.
132. Nickerson, M. L., A. D. Bosley, J. S. Weiss, B. N. Kostiha, Y. Hirota, W. Brandt, D. Esposito, S. Kinoshita, L. Wessjohan, S. G. Morham, et al. 2013. The UBIAD1 prenyltransferase links menaquinone-4 synthesis to cholesterol metabolic enzymes. Hum. Mutat. 34: 317-329.
133. McGarvey, T. W., T. Nguyen, J. E. Tomaszewski, F. C. Monson, and S. B. Malkowicz. 2001. Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder. Oncogene. 20: 1042-1051. (Pubitemid 32238853)
134. McGarvey, T. W., T. Nguyen, R. Puthiyaveettil, J. E. Tomaszewski, and S. B. Malkowicz. 2003. TERE1, a novel gene affecting growth regulation in prostate carcinoma. Prostate. 54: 144-155. (Pubitemid 36120330)
135. Fredericks, W. J., J. Sepulveda, P. Lal, J. E. Tomaszewski, M-F. Lin, T. McGarvey, F. J. Rauscher III, and S. B. Malkowicz. 2013. The tumor suppressor TERE1 (UBIAD1) prenyltransferase regulates the elevated cholesterol phenotype in castration resistant prostate cancer by controlling a program of ligand dependent SXR target genes. Oncotarget. 4: 1075-1092.
136. Yaguchi, M., K. Miyazawa, T. Katagiri, J. Nishimaki, M. Kizaki, K. Tohyama, and K. Toyama. 1997. Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of alltrans retinoic acid. Leukemia. 11: 779-787. (Pubitemid 27279724)
137. Karasawa, S., M. Azuma, T. Kasama, S. Sakamoto, Y. Kabe, T. Imai, Y. Yamaguchi, K. Miyazawa, and H. Handa. 2013. Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis. Mol. Pharmacol. 83: 613-620.
138. Ozaki, I., H. Zhang, T. Mizuta, Y. Ide, Y. Eguchi, T. Yasutake, T. Sakamaki, R. G. Pestell, and K. Yamamoto. 2007. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. Clin. Cancer Res. 13: 2236-2245. (Pubitemid 46649893)
139. Yamaguchi, M., and M. N. Weitzmann. 2011. Vitamin K2 stimulates osteoblastogenesis and suppresses osteoclastogenesis by suppressing NF-κB activation. Int. J. Mol. Med. 27: 3-14.
140. Wadelius, M., L. Y. Chen, J. D. Lindh, N. Eriksson, M. J. Ghori, S. Bumpstead, L. Holm, R. McGinnis, A. Rane, and P. Deloukas. 2009. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 113: 784-792.
141. Jaques, L. B., G. J. Millar, and J. W. T. Spinks. 1954. The metabolism of the K-vitamins. Schweiz. Med. Wochenschr. 84: 792-796.
142. 14C-menadione. Life Sci. 7: 153-158.
143. Bhagavan, H. N., and R. K. Chopra. 2007. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 7 (Suppl) : S78-S88. (Pubitemid 46712234)